Back to Awarded Treatment Trials
Awarded Trial: 01T-400
Grant ID
01T-400
Illness
Schizophrenia
Primary Drug/Intervention
N-acetyl cysteine
Primary Dosage
2 g twice per day
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Berk
Sample Size
140
Duration of Study Period for Each Subject
6 months
Outcome Measurements
PANSS, CGI, Global Assessment of Functioning, AIMS, Simpson-Angus, Barnes Akathisia
Results
There was a significant effect of active drug on CGI, PANSS negative, PANSS general and PANSS total scores. There was also a reduction in alcohol and substance use and akathisia associated with drug treatment.
Publication
Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Judd F, Katz F, Katz P, Ording-Jespersen S, Little J, Conus P, Cuenod M, Do KQ, Bush AI. N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial. Biol Psychiatry. 2008 Sep 1;64(5):361-8. doi: 10.1016/j.biopsych.2008.03.004. Epub 2008 Apr 23.
Link
http://www.ncbi.nlm.nih.gov/pubmed/18436195
PI Name
Michael Berk
Degree
MD
Center
Mental Health Research Institute
Institution
University of Melbourne
Address
155 Oak Street
City or Town
Parkville
State or Province
Victoria
Zip or Postal Code
3052
Country
Australia
Email Address
mikebe@barwonhealth.org.au